相关实验视频

Updated: May 28, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

向腺可以增强MSS结直肠癌的免疫疗法,而结直肠癌患有EGFRvIII突变

Fei Sun¹, Fangzhen Yao¹, Chunting Zeng¹

¹Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Journal for immunotherapy of cancer

|February 13, 2025

概括

具有EGFRvIII突变的微卫星稳定结直肠癌 (MSS CRC) 显示对免疫疗法的耐药性. 向腺结合抗PD-1疗法可以通过重塑瘤微环境来克服这种抵抗.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症基因组学癌症基因组学

背景情况:

微卫星稳定结直肠癌 (MSS CRC) 常常会抵抗免疫疗法.
以表皮生长因子受体 (EGFR) 为向的疗法显示出潜力,但需要更好的患者分层来增强免疫疗法.
不充分的患者选择可能解释了当前免疫疗法在MSSCRC中的有限临床益处.

研究的目的:

确定一种独特的MSS CRC亚型,可以从组合疗法中获益.
研究EGFR变异型III (EGFRvIII) 在MSSCRC免疫疗法耐药性中的作用.
探索结合腺抑制与抗PD-1疗法在EGFRvIII突变的MSSCRC.中结合的疗效.

主要方法:

来自MSS CRC患者的循环瘤细胞和瘤组织的分析,这些患者接受了 cetuximab.
在患者样本中评估EGFRvIII表达和免疫透.
使用EGFRvIII CRC的合成小鼠模型来测试联合腺抑制和抗PD-1疗法.

主要成果:

存在于~10%的MSSCRC中的EGFRvIII突变与对 cetuximab的反应不佳相关.
经EGFRvIII突变的MSSCRC表现出一种由腺驱动的免疫抑制瘤微环境 (TME).
与腺抑制剂和抗PD-1的联合治疗在EGFRvIIICRC模型中逆转了 cetuximab耐药性和提高了抗PD-1疗效.

结论:

EGFRvIII阳性MSSCRC被确定为一种独特的亚型,具有由腺介导的免疫抑制TME.
向腺显著提高了MSS CRC中的抗PD-1疗效,特别是在EGFRvIII突变亚型中.
这项研究突出了针对免疫疗法耐药性结直肠癌的一个子集的新疗法策略.

关键词:

氨酸 (Adenosine) 是一种氨酸.结肠直肠癌是什么意思免疫疗法免疫疗法

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...